Full text is available at the source.
Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review
Apr 2, 2016Health technology assessment (Winchester, England)
Sedation with Alpha-2 Agonists in Mechanically Ventilated Adults in Intensive Care: A Systematic Review
AI simplified
Abstract
Eighteen randomized controlled trials involving 2489 adult patients were analyzed to compare sedation effects in mechanically ventilated ICU patients.
- Dexmedetomidine may lead to a shorter average ICU stay by 1.26 days and a shorter time to extubation by 1.85 days compared to propofol or benzodiazepines.
- No significant difference in mortality rates was found between dexmedetomidine and propofol or benzodiazepines.
- Dexmedetomidine was associated with a higher risk of bradycardia, with a risk ratio of 1.88.
- The evidence for clonidine's use in ICUs is very limited.
- Variability in trial populations, sedative dosages, and outcome assessments indicates a generally high or unclear risk of bias in the included studies.
AI simplified
BACKGROUND: Care of critically ill patients in intensive care units (ICUs) often requires potentially invasive or uncomfortable procedures, such as mechanical ventilation (MV). Sedation can alleviate pain and discomfort, provide protection from stressful or harmful events, prevent anxiety and promote sleep. Various sedative agents are available for use in ICUs. In the UK, the most commonly used sedatives are propofol (Diprivan(®), AstraZeneca), benzodiazepines [e.g. midazolam (Hypnovel(®), Roche) and lorazepam (Ativan(®), Pfizer)] and alpha-2 adrenergic receptor agonists [e.g. dexmedetomidine (Dexdor(®), Orion Corporation) and clonidine (Catapres(®), Boehringer Ingelheim)]. Sedative agents vary in onset/duration of effects and in their side effects. The pattern of sedation of alpha-2 agonists is quite different from that of other sedatives in that patients can be aroused readily and their cognitive performance on psychometric tests is usually preserved. Moreover, respiratory depression is less frequent after alpha-2 agonists than after other sedative agents.
OBJECTIVES: To conduct a systematic review to evaluate the comparative effects of alpha-2 agonists (dexmedetomidine and clonidine) and propofol or benzodiazepines (midazolam and lorazepam) in mechanically ventilated adults admitted to ICUs.
DATA SOURCES: We searched major electronic databases (e.g. MEDLINE without revisions, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE and Cochrane Central Register of Controlled Trials) from 1999 to 2014.
METHODS: Evidence was considered from randomised controlled trials (RCTs) comparing dexmedetomidine with clonidine or dexmedetomidine or clonidine with propofol or benzodiazepines such as midazolam, lorazepam and diazepam (Diazemuls(®), Actavis UK Limited). Primary outcomes included mortality, duration of MV, length of ICU stay and adverse events. One reviewer extracted data and assessed the risk of bias of included trials. A second reviewer cross-checked all the data extracted. Random-effects meta-analyses were used for data synthesis.
RESULTS: Eighteen RCTs (2489 adult patients) were included. One trial at unclear risk of bias compared dexmedetomidine with clonidine and found that target sedation was achieved in a higher number of patients treated with dexmedetomidine with lesser need for additional sedation. The remaining 17 trials compared dexmedetomidine with propofol or benzodiazepines (midazolam or lorazepam). Trials varied considerably with regard to clinical population, type of comparators, dose of sedative agents, outcome measures and length of follow-up. Overall, risk of bias was generally high or unclear. In particular, few trials blinded outcome assessors. Compared with propofol or benzodiazepines (midazolam or lorazepam), dexmedetomidine had no significant effects on mortality [risk ratio (RR) 1.03, 95% confidence interval (CI) 0.85 to 1.24, I (2) = 0%; p = 0.78]. Length of ICU stay (mean difference -1.26 days, 95% CI -1.96 to -0.55 days, I (2) = 31%; p = 0.0004) and time to extubation (mean difference -1.85 days, 95% CI -2.61 to -1.09 days, I (2) = 0%; p < 0.00001) were significantly shorter among patients who received dexmedetomidine. No difference in time to target sedation range was observed between sedative interventions (I (2) = 0%; p = 0.14). Dexmedetomidine was associated with a higher risk of bradycardia (RR 1.88, 95% CI 1.28 to 2.77, I (2) = 46%; p = 0.001).
LIMITATIONS: Trials varied considerably with regard to participants, type of comparators, dose of sedative agents, outcome measures and length of follow-up. Overall, risk of bias was generally high or unclear. In particular, few trials blinded assessors.
CONCLUSIONS: Evidence on the use of clonidine in ICUs is very limited. Dexmedetomidine may be effective in reducing ICU length of stay and time to extubation in critically ill ICU patients. Risk of bradycardia but not of overall mortality is higher among patients treated with dexmedetomidine. Well-designed RCTs are needed to assess the use of clonidine in ICUs and identify subgroups of patients that are more likely to benefit from the use of dexmedetomidine.
STUDY REGISTRATION: This study is registered as PROSPERO CRD42014014101.
FUNDING: The National Institute for Health Research Health Technology Assessment programme. The Health Services Research Unit is core funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates.
Related papers
Apr '15
Using alpha-2 agonists for long-term sedation in critically ill patients on mechanical ventilators
cited by 50 papers
systematic review
Dec '23
Using Alpha 2 Agonists for Sedation to Improve Recovery and Cost Outcomes in Critically Ill Patients: UK Multicenter Phase 3 Trial Plan
top 20% journal
cited by 8 papers
clinical trial protocol
Aug '13
Comparing benzodiazepine and non-benzodiazepine sedation in critically ill adults on ventilators
top 5% journal
cited by 234 papers
systematic review
May '25
Sedation with Dexmedetomidine or Clonidine Compared to Propofol in Critically Ill Patients
cited by 38 papers
randomized controlled trial
Mar '12
Comparing dexmedetomidine, midazolam, and propofol for sedation during long-term mechanical ventilation in two trials
top 1% journal
cited by 797 papers
randomized controlled trial
Dec '15
Effectiveness of Alpha-2 Agonists for Sedation in Critically Ill Children
top 20% journal
cited by 59 papers
systematic review
Jun '13
Is Dexmedetomidine Ready for Routine Use in Intensive Care?
top 5% journal
cited by 21 papers
comment
May '25
Cost-Effectiveness of α2 Agonists for IV Sedation in Critically Ill Patients
top 2% journal
cited by 2 papers
research support, non-u.s. gov't
Jul '13
Early focused sedation compared to usual sedation in critically ill patients on ventilators: a pilot study
top 5% journal
cited by 138 papers
randomized controlled trial
Sep '16
Using alpha-2 drugs for sedation in brain-injured patients on ventilators: a review plan
top 5% journal
cited by 5 papers
journal article